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Objective To propose and assess a composite endpoint (CE) of neonatal beneﬁt based
on neonatal mortality and morbidities by gestational age (GA) for use in preterm labor
clinical trials.
Study Design A descriptive, retrospective analysis of the Medical University of South
Carolina Perinatal Information System database was conducted. Neonatal morbidities
were assessed for inclusion in the CE based on clinical signiﬁcance/risk of childhood
neurodevelopmental impairment, frequency, and association with GA in a mother–
neonate linked cohort, comprising women with uncomplicated singleton pregnancies
delivered at 24 weeks’ GA.
Results Among 17,912 mother–neonate pairs, neonates were at a risk of numerous
severe but infrequent morbidities. Clinically important, predominantly rare events
were combined into a CE comprising neonatal mortality and morbidities, which
decreased in frequency with increasing GA. The highest CE frequency occurred at
<31 weeks. High frequency of respiratory distress syndrome, bronchopulmonary
dysplasia, and sepsis drove the CE. Median length of hospital stay was longer at all
GAs in those with the CE compared with those without.
Conclusions Descriptive epidemiological assessment and clinical input were used to
develop a CE to measure neonatal beneﬁt, comprising clinically meaningful outcomes.
These empirical data and CE allowed trials investigating tocolytics to be sized appropriately.
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In 2010, 11% of live births worldwide were preterm (occurring before 37 weeks of gestation).1 Variation in estimated
preterm birth rates was seen across countries, from approximately 5% in Europe to 18% in Africa.1 While approximately
one-third of preterm births result from medical intervention
to resolve maternal or fetal medical indications, 40 to 45%
result from spontaneous preterm labor, the underlying
pathogenesis of which is not fully understood.2 Preterm
birth is the most common direct cause of neonatal death
and indirectly affects infant mortality rates through associated morbidities.3–5 Consequences for the neonate can
persist into later life, with sequelae such as visual and
hearing impairment, lung disease, cardiovascular disorders,
and neurodevelopmental impairments.3,6–9 Preterm birth
also imposes a substantial socioeconomic burden on families
(cost of care, loss of wages, and emotional impact) and wider
society (acute and chronic health-care costs).7
The global burden of preterm birth highlights the need for
effective drugs to stop preterm labor, and, as such, tocolytic
development is a discovery research priority of the World
Health Organization’s Every Newborn Action Plan to End
Preventable Deaths.10 The goal of current tocolytics for the
management of preterm labor is to prolong gestation, allowing time for the administration of antenatal corticosteroids
or maternal transfer to another medical facility,11 but there is
very limited evidence of a measurable beneﬁt of tocolytics on
neonatal outcomes.7,12 However, in considering atosiban for
the treatment of preterm labor, the U.S. Food and Drug
Administration stated that demonstrating prolongation of
pregnancy was no longer sufﬁcient for the approval of new
tocolytics; randomized controlled trials (RCTs) of tocolytics
should have a primary endpoint of neonatal beneﬁt. Preterm
birth study endpoints vary widely; a recent systematic
review reported 72 different primary outcomes in 103
RCTs among diverse patient populations.13 The majority
measured delay to delivery or perinatal mortality, and only
ﬁve studies used a composite endpoint of neonatal morbidities and death, deﬁned differently among each study.13 In
addition, there are sparse empirical data available in the
literature on the incidence of composite endpoints across the
spectrum of gestational age (GA).
Small population sizes are common in preterm birth RCTs,
and the infrequency of some severe morbidities underscores
the need for a suitable composite endpoint to establish
neonatal beneﬁt. The European Network for Health Technology Assessment states that composite endpoints are appropriate in clinical trials in the absence of a single suitable
primary endpoint. Moreover, there should be empirical and
clinical evidence of the value of each component, and components should not be included in the composite if treatment
is not expected to affect this variable.14
Clinical development of new tocolytics (such as retosiban
currently in development by GlaxoSmithKline15,16) is
required to demonstrate both prolongation of pregnancy
and a beneﬁt to the neonate. To inform the retosiban clinical
trial program, the objective of this study was to use realworld empirical data to determine the frequencies of neonatal morbidities and mortality by GA in the patient populaAmerican Journal of Perinatology Reports
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tion of interest and to propose a clinically meaningful
composite endpoint to measure neonatal beneﬁt in RCTs.

Material and Methods
Data Source and Patient Population
The study data source was the Medical University of South
Carolina (MUSC) Perinatal Information System (PINS), a
research-quality perinatal database for all women delivering
at the MUSC, which is a regional tertiary referral hospital in
the southeastern United States. An active surveillance system
was used to populate the MUSC PINS, in which data were
abstracted from clinical notes speciﬁcally for entry into the
database. Data were entered by trained personnel, and
logical error checks were performed routinely on all data;
inter- and intrarater reliability both exceed 97%.17 The MUSC
PINS database included detailed information on each
mother’s medical history, linked to neonatal data (such as
medical diagnoses, medications, surgical procedures, and
laboratory tests) from delivery to hospital discharge; however, comprehensive antenatal care information from outside the hospital setting was not available. Ethical approval
for this study was provided by the Institutional Review Board
for Human Research at the MUSC.
A descriptive, retrospective cohort study of the MUSC
PINS data was conducted from 2000 to 2011. The study
cohort (termed simulated trial population) was created to
match, as closely as possible within the constraints of the
database, the population within the phase III retosiban
clinical trials which was women with singleton uncomplicated pregnancies and intact membranes in preterm labor
between 240/7 and 336/7 weeks of GA (►Fig. 1). Women
with multiple gestation pregnancies were excluded. Maternal pregnancy complications, as determined by trial exclusion criteria, were preterm prelabor rupture of membranes,
hypertensive disorders of pregnancy (including severe
preeclampsia and eclampsia-related conditions), placental
conditions (such as placenta previa and placental abruption), and intra-amniotic infection or intrauterine growth
restriction (see ►Fig. 1 for full list of maternal complications used as exclusion criteria). Neonates with prespeciﬁed severe or life-threatening congenital conditions were
also excluded (►Fig. 1). As antenatal care was not captured
within the MUSC PINS, preterm labor diagnoses were not
available and therefore did not form part of the inclusion
criteria. All mother–neonate pairs who met the aforementioned inclusion and exclusion criteria and delivered at
24 weeks’ GA were included in the simulated trial population (►Fig. 1).

Deﬁnition of Composite Endpoint
Clinical/Epidemiological Assessment of Data
The study investigated the frequency of approximately 100
neonatal outcomes (including neonatal medical diagnoses,
surgical procedures, medication use, laboratory tests) by GA
in the MUSC PINS database. The decision to consider further
or to exclude each neonatal outcome in a potential composite
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all live births ≥24 weeks GA
from 2000–2011
n = 26 495
n = 2105

Singleton births
n = 24 390

• Twins: n = 1935
• Triplets+: n = 170

Women with
n = 5935
(24.3% of singleton births)

Neonates with congenital
or chromosomal
n = 858
(3.5% of singleton births)

Used for composite
endpoint and
mortality analyses
all uncomplicated births
n = 17 957

• Severe pre-eclampsia: n = 980 (4.0%)
• Eclampsia: n = 37 (0.2%)
• HELLP syndrome: n = 148 (0.6%)
• IUGR: n = 1030 (4.2%)
• Polyhydramnios: n = 307 (1.3%)
• Oligohydramnios: n = 750 (3.1%)
• pPROM: n = 2264 (9.3%)
n = 1101 (4.5%)
• Placenta previa: n = 220 (0.9%)
n = 236 (1.0%)

Neonates who died
before hospital discharge,
excluding those with
AND excluding those
born to mothers with

Used for component
frequency analysis

n = 45
(0.2% of singleton births)

(live born singletons
excluding all neonates with
congenital anomalies
AND those who died prior
to discharge AND those
born to mothers with
n = 17 912
Fig. 1 Patient attrition from the complete MUSC PINS database population to the simulated trial population for analyses. Maternal
complications (as listed in the correspondingly labeled box) were not mutually exclusive and therefore women could have more than one
complication. Congenital abnormalities were achondrogenesis type II, anencephaly, arteriovenous malformation, autosomal recessive
polycystic kidney disease, bilateral dysplastic kidneys, bilateral multicystic kidneys with renal failure, bilateral renal agenesis, congenital
hydrocephaly, congenital renal abnormality/agenesis, diaphragmatic hernia, duodenal atresia, exencephaly, exstrophy of bladder, gastroschisis,
genitourinary cystic/dysplastic obstruction, harlequin fetus, hydronephrosis, hydrops fetalis (immune and nonimmune), hypoplastic left heart,
imperforate anus, inborn error of metabolism, iniencephaly, Meckel–Gruber’s syndrome, mixed dysplastic/cystic/agenic disorders with kidney
failure, myelomeningocele, esophageal atresia, omphalocele, osteogenesis imperfecta type II, Potter’s syndrome, tetralogy of Fallot, total
anomalous pulmonary venous return, tracheoesophageal ﬁstula, transposition of the great arteries, trisomy 13, trisomy 18, and trisomy 21. GA,
gestational age; HELLP syndrome, hemolysis, elevated liver enzymes, low platelet count; IUGR, intrauterine growth restriction (deﬁned as fetal
weight below the 10th percentile for GA); MUSC, Medical University of South Carolina; PINS, Perinatal Information System; pPROM, preterm
prelabor rupture of membranes.

was made by the authors, additional members of the
GlaxoSmithKline clinical team, and a consulting neonatologist (as detailed in the Acknowledgments section). They
reviewed each of the outcomes and assessed its clinical
signiﬁcance, frequency of occurrence, association with
GA, variability of diagnosis, and severity (particularly the

associated risk of neurodevelopmental impairment), as well
as published literature. Morbidities were considered for
inclusion in the composite if they were of particular clinical
relevance, such as predictors of long-term neurodevelopmental impairment; this was not dependent on their
reported frequency.
American Journal of Perinatology Reports
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Components and Calculation of the Composite Endpoint
The following morbidities were identiﬁed as the most appropriate components for a composite endpoint to investigate
neonatal beneﬁt of interventions to postpone preterm delivery based on their clinical signiﬁcance and relationship with
early GA: fetal/neonatal death, respiratory distress syndrome
requiring continuous positive airway pressure or mechanical
ventilation, bronchopulmonary dysplasia (BPD), severe
intraventricular hemorrhage (grade 3 or 4), periventricular
leukomalacia (with periventricular cyst or with porencephalic cyst or acquired hydrocephaly), retinopathy of prematurity (conﬁrmed as stage 3 or any stage requiring laser
treatment), conﬁrmed sepsis, meningitis, and necrotizing
enterocolitis (surgically treated).
To calculate the overall frequency of the composite endpoint, the data for each individual neonate were assessed. For
any individual, if any of the morbidities were present, then the
score was 1, otherwise the score was 0; the scores from all
individuals were summed by week of GA to form a GA-speciﬁc
count or numerator (by individual week). The denominator
population was the simulated trial cohort (►Fig. 1) but
included neonates who died, as death was an outcome in
the composite; denominators were also calculated by week of
GA. Deaths were deﬁned as all deaths before hospital discharge, including antepartum and intrapartum deaths.
Composite endpoint frequencies were also stratiﬁed by sex
and race. This stratiﬁcation allowed the endpoint to be evaluated against established neonatal morbidity associations.18,19

Statistical Software
All analyses were conducted in SAS version 9.3 (SAS Institute
Inc., Cary, NC, United States).

Results
Study Population Characteristics
The overall MUSC population comprised 26,495 women;
population attrition from the overall population extracted
from the MUSC PINS database and reasons for patient exclusion (as well as details of complications and abnormalities
resulting in exclusion from the cohort) are detailed in ►Fig. 1.
From the overall population, 17,912 mother–neonate pairs
were included in the simulated trial population (67.6%).
Maternal demographics of the simulated trial population are
shown in ►Table 1. Women in the study had a mean age of
26 years (standard deviation: 6.1 years; range: 13–51 years),
and almost half of the population were black (44.7%). Just over
half were on government-funded social welfare for lowincome individuals (Medicaid/public/medically indigent;
52.7%) and a third (33.8%) had 13 years education, equating
to a university or other higher-level education. In the simulated
trial population, 8.2% of the births were preterm in contrast to
28.5% of the overall population (data not shown), indicative of
the high-risk referral status of the hospital.
Neonatal demographic characteristics and composite
morbidities of the simulated trial population are shown
in ►Table 2 and ►Fig. 2A, with rates of additional morbidities
in ►Supplementary Table S1 (online only). As expected, a
American Journal of Perinatology Reports
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Table 1 Characteristics of women in the simulated trial
population in the MUSC PINS between 2000 and 2011
Characteristic

N

Overall

N ¼ 17,912

%a

Maternal age (y)a
12–18

853

8.6

19–29

6,286

63.3

30–39

2,574

25.9

 40

212

2.1

Unknown

7,987

Maternal race
White

4,997

27.9

Black

8,011

44.7

Hispanic

4,557

25.4

Other

347

1.9

Health insurancea–c
Commercial/private

4,083

22.8

Self-pay

4,393

24.5

Medicaid/public/medically
indigent

9,435

52.7

 12 y

8,416

66.2

 13 y

4,298

33.8

Unknown

5,198

Education levela

GA at birth (wk)
24–27

136

0.8

28–33

445

2.5

34–36

888

5

16,443

91.8

Tocolysis (included
MgSO4, terbutaline,
indomethacin, nifedipine,
ritodrinee)

300

51.6

Antenatal steroids (included
betamethasone or
dexamethasone)

487

83.8

 37
Maternal medications

d

Abbreviations: GA, gestational age; MUSC, Medical University of South
Carolina; PINS, The MUSC Perinatal Information System.
Note: Rounding of percentages of patients may result in characteristic
groups summing to >100.
a
Percentage calculated only among those with known data. bOne
woman with unknown insurance status. cIn the United States, health
insurance is required to pay for medical expenses (commercial/private
insurance is employer-funded, self-pay is payment at the point of care,
Medicaid/public/medically indigent insurance is government-funded,
social welfare for low-income individuals). dPercentage calculated
among the 581 women with neonates of <34 weeks’ GA only
(indicated population). eRitodrine was discontinued in the United
States in March 2010.
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Table 2 Neonatal characteristics in the simulated trial population
GA at birth (wk)a
24–27
(n ¼ 136)

28–33
(n ¼ 445)

34–36
(n ¼ 888)

37
(n ¼ 16,443)

Total
(N ¼ 17,912)

Male

79 (58.1)

232 (52.1)

465 (52.4)

8,353 (50.8)

9,129 (51)

Female

57 (41.9)

213 (47.9)

423 (47.6)

8,090 (49.2)

8,783 (49)

White

46 (33.8)

147 (33)

264 (29.7)

4,510 (27.4)

4,967 (27.7)

Black

82 (60.3)

268 (60.2)

470 (52.9)

7,196 (43.8)

8,016 (44.8)

Hispanic

8 (5.9)

27 (6.1)

146 (16.4)

4,385 (26.7)

4,566 (25.5)

Other

0

3 (0.7)

8 (0.9)

352 (2.1)

363 (2)

10 (2.2)

536 (60.4)

15,141 (92.1)

15,687 (87.6)

0

149 (33.5)

246 (27.7)

938 (5.7)

1,333 (7.4)

136 (100)

286 (64.3)

106 (11.9)

359 (2.2)

887 (5)

0

8 (1.8)

443 (49.9)

12,899 (78.4)

13,350 (74.5)

Neonatal variable
Neonatal sex, n (%)

Neonatal race, n (%)

Highest level neonatal ward admission during hospital stay, n (%)
Normal nursery (level I)
NICU level II

b

NICU level IIIc

0

Length of hospital stay, n (%)
<3d

d

3 d to 1 wk

1 (0.7)

40 (9)

331 (37.3)

3,290 (20)

3,662 (20.4)

1 wk to 1 mo

0

245 (55.1)

106 (11.9)

212 (1.3)

563 (3.1)

1–2 mo

42 (30.9)

128 (28.8)

6 (0.7)

31 (0.2)

207 (1.2)

2–3 mo

58 (42.6)

20 (4.5)

0

7 (0)

85 (0.5)

 3 mo

35 (25.7)

4 (0.9)

2 (0.2)

4 (0)

45 (0.3)

Abbreviations: GA, gestational age; NICU, neonatal intensive care unit.
a
GA was analyzed by week but is summarized here by range for clarity. bNICU level II is a special care nursery providing care for neonates born at 32
weeks’ GA and weighing  1,500 g who are physiologically immature or are moderately ill with problems that are expected to resolve rapidly
without urgent subspecialty services. cNICU level III can provide sustained life support, provide comprehensive care for neonates born at <32 weeks’
GA and weighing <1,500 g or neonates of any GA/birth weight with critical illness, give ready access to pediatric specialists including surgeons, can
provide respiratory support including ventilation and inhaled nitric oxide, and perform emergency advanced imaging. dNeonate transferred to
another hospital for continued care at day 7.

clear relationship was seen with GA for both neonatal ward
use and length of hospital stay (birth hospitalization). All
extremely preterm babies (24–27 weeks’ GA) required level
III neonatal intensive care unit (NICU) treatment, and 25.7%
were hospitalized for 3 months. Similarly, almost 98% of
moderately preterm babies (28–33 weeks’ GA) required level
II/III NICU care, and >30% remained in the hospital for 1
month.

Neonatal Morbidities and Composite Endpoint
Development
In total, 3.4% of the population were positive to the composite endpoint. Of those with the composite endpoint, 84.9%
were born preterm compared with 5.6% without the composite. The frequency of the composite endpoint and the
individual frequencies of neonatal mortality and morbidities
by individual week of GA at delivery are shown in ►Fig. 2A .
The frequency of the composite and all component morbidities decreased steeply with increasing GA, with the highest
frequency of morbidity seen before 31 weeks, dropping to

very few events in the full-term population (37 weeks). For
the majority of other key neonatal morbidities, a similar
inverse relationship was seen with increasing GA, with most
events among the extremely and moderately preterm
infants. The exception to this was hypoglycemia, which
occurred in approximately 15 to 22% in each of the preterm
groups (►Supplementary Table S1, online only).
The frequency of the composite was driven by the frequency of respiratory distress syndrome, BPD, and sepsis.
Respiratory distress syndrome was the most frequent morbidity at every GA week, apart from 35 and 36 weeks, where
BPD was more common. Other components were rarer,
occurring between 3 and 12% of the extremely premature
(24–27 weeks) group, and 1 and 3% of the moderately
preterm group (28–33 weeks’ GA). When race (black, white)
and sex stratiﬁcation by GA was performed, there was
considerable variability in the composite endpoint frequency, particularly between 27 and 36 weeks’ GA in each
subgroup; after 37 weeks, the composite frequency was
similar between these subgroups (►Fig. 2B). While the
American Journal of Perinatology Reports
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100

120

BPD

80

Sepsis
PVL (cpve)
IVH 3/4
ROP 4 / ROP treated
Death (*)
Meningi s
NEC (surgical)

70
60
50
40
30

100
Length of stay (days)

Frequency of outcome (%)
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Composite (*)
RDS (CPAP/VENT)

90

Median with composite
Median without composite

80
60
40

20

20
10
0

A

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 ≥42
Gesta onal age at birth (Weeks)

120

Overall composite
Male-White
Female-White
Male-Black
Female-Black

100
Frequency of composite (%)

e30

80
60
40
20
0

B

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 ≥42
Gesta onal age at birth (Weeks)

Fig. 2 (A) Frequency of individual neonatal morbidities and mortality
in the composite. (B) Race/sex stratiﬁcation of the composite in white
and black neonates. BPD, bronchopulmonary dysplasia; CPAP, continuous positive airway pressure; CPVE, cysts or porencephaly and
ventricular enlargement; IVH, intraventricular hemorrhage; NEC,
necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS,
respiratory distress syndrome; ROP, retinopathy of prematurity;
VENT, ventilation. Frequency of composite endpoint and deaths
calculated in 17,957 births following uncomplicated pregnancies;
frequency of morbidities calculated in live uncomplicated births only
(n ¼ 17,912).

smaller sample sizes in the subgroups may partly explain the
variability between GA groups, overall trends can be seen.
The frequency of the composite in black neonates of either
sex tended to be below the rate seen for the overall population, whereas white neonates had composite rates slightly
higher than those in the overall population, though this was
not statistically determined.
Median length of stay of the birth hospitalization was
consistently longer at each week of GA among those with the
composite endpoint compared with those without (►Fig. 3).
It fell sharply from 102 days (interquartile range [IQR]: 88–
116) at 24 weeks’ GA to 6 to 8 days at 36 to 38 weeks’ GA, after
which a slight upturn was seen. The composite was not
present in only seven neonates before 30 weeks’ GA; median
length of stay was 29 days (IQR: 21–34) at 30 weeks’ GA,
dropping to 2 days (IQR: 1–2) at 35 weeks and remaining at
this level thereafter.

Discussion
Current tocolytic agents do not necessarily demonstrate
neonatal beneﬁt, despite often successfully prolonging pregAmerican Journal of Perinatology Reports
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0
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 ≥42

Fig. 3 Median length of stay in neonates with and without the
composite. Composite endpoint excludes death.

nancy.11 As a result, it is now recommended that preterm
labor RCTs should have an additional primary endpoint of
neonatal beneﬁt.20 Despite this, there are no standard endpoints in clinical trials involving women who might deliver
preterm neonates.13,17,21 The Core Outcomes for Prevention
of Preterm birth project led by the Core Outcomes in
Women’s Health initiative aims to obtain expert consensus
about the most relevant and clinically meaningful endpoints
in this ﬁeld to facilitate effective synthesis of evidence in
RCTs and help develop robust recommendations for clinical
practice.22 These initiatives will be valuable in providing
expert clinical opinion regarding the core outcome measures
of neonatal beneﬁt in preterm birth; however, it is also
important to provide empirical evidence of the frequency
of the proposed endpoints in similar populations to that of an
RCT, hence the use of real-world data in this study.
Data from this study were used to directly inform sample
size planning for the ongoing retosiban clinical trials, as the
database hospital site closely resembles the study centers for
the RCT program. We took into consideration that, because of
the stipulated population characteristics, the MUSC rates are
likely to represent the upper limit of plausibility of those
seen in RCTs. However, this similarity between the populations should maximize the likelihood of appropriate study
power to determine neonatal beneﬁt; indeed, an earlier
preterm birth intervention study noted that the use of
historical data from dissimilar study centers might have
been at least partly responsible for negative results.23 Replication of the frequency of this composite endpoint and
individual neonatal morbidities is ongoing using other U.S.
and European databases.
In this study, data were descriptively analyzed from a
cohort of almost 18,000 mother–neonate pairs identiﬁed
from the MUSC PINS database, and components of the
proposed composite were selected following examination
of approximately 100 neonatal morbidities. Neonates were at
a risk of a range of severe but predominantly infrequent
morbidities, which suggested that it would be appropriate to
combine clinically meaningful rare events into a single
composite measure, particularly as morbidities rarely
occurred singly but were commonly clustered.

Composite Endpoint of Neonatal Benefit
The composite represents a set of important comorbidities inversely associated with GA at birth and resulting in a
longer length of hospital stay. These morbidities are directly
related to recognized health burdens. Most of the included
morbidities substantially increase the risk of later neurodevelopment impairment such as cerebral palsy, developmental delay, and visual/hearing impairments. For example,
BPD24 and necrotizing enterocolitis25 are direct risk factors
for neurodevelopment impairment, and intraventricular
hemorrhage, through its strong association with white matter damage, indirectly increases the risk of neurodevelopment impairment.26
A strong inverse relationship of the composite with increasing GA was seen, and this declining incidence of morbidities is
in agreement with previous studies in wider populations.27,28
The largest variability in sex and race, also observed between
weeks 30 and 35, is consistent with previous studies.18,19 It is
well established that male neonates have a higher mortality
rate compared with female neonates,19 which was demonstrated in this study. Moreover, black preterm neonates (>28
weeks’ GA) have the lowest mortality rate compared with
white or Hispanic neonates,18 which was also reﬂected within
this composite analysis.
This study has several limitations. The MUSC database
draws from a single center based in the southeastern
United States, with a predominantly black and lower socioeconomic status population. Marked variation in perinatal
and neonatal outcomes have been observed across different
regions and countries;29 therefore, the study population
used in this analysis may not be broadly generalizable to
that of a global RCT. However, the MUSC site does resemble
the proposed study centers in the retosiban RCT program
(i.e., hospitals with high-level NICU capabilities).15,16 The
study period spanned 11 years, over which time many
components of neonatal care have improved, which may
lead to reduced event frequency in more recently collected
data. A recent U.S. study indicated that mortality and rates of
several of the included morbidities (sepsis, intraventricular
hemorrhage, periventricular leukomalacia, and retinopathy
of prematurity) have decreased slightly between 1993 and
2012, though the rates of BPD did not.30 Further limitations
of the study include the risk for bias during chart abstraction
from medical records into the database; this was minimized
by using data abstractors with training in medical terminology and implementation of strict guidelines on priority of
data abstraction when multiple sources were available. In
addition, data validity was further assessed by having a 10%
random sample of charts abstracted by a different neonatologist who was not working in the hospital at the time of
original data collection. The study population included all
women with singleton, uncomplicated pregnancies but not
those with a diagnosis of preterm labor (as would be
included in the trial) as this was not captured within the
database. Finally, within the clinical trial setting, outcomes
will be deﬁned using more speciﬁc clinical criteria than were
able to be captured within a database, which may inﬂuence
the frequency of the morbidities (Supplementary Table S2
[online only] for trial versus database deﬁnitions).
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Neonates in this descriptive analysis of a real-world singlecenter database cohort were at a risk of several clinically
meaningful but predominantly infrequent morbidities. While
maintaining clinical relevance, we combined eight of these
morbidities with mortality into a composite endpoint. Use of a
composite endpoint may improve the statistical efﬁciency of
RCTs for tocolytics required to demonstrate neonatal beneﬁt,
and the empirical data generated were used to directly inform
sample size calculations for such trials.
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